Steven E Patterson

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Cyanide antidotes for mass casualties: water-soluble salts of the dithiane (sulfanegen) from 3-mercaptopyruvate for intramuscular administration
    Steven E Patterson
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Med Chem 56:1346-9. 2013
  2. pmc Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA
    Antimicrob Agents Chemother 56:1942-8. 2012
  3. pmc Novel, orally effective cyanide antidotes
    Herbert T Nagasawa
    Center for Drug Design, University of Minnesota, Minneapolis 55455, USA
    J Med Chem 50:6462-4. 2007
  4. pmc 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors
    Jonathan M Rawson
    Institute for Molecular Virology, University of Minnesota, 18 242 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA Molecular and Cellular Developmental Biology and Genetics Graduate Program, Medical School, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem 21:7222-8. 2013
  5. doi request reprint Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis
    Laurent F Bonnac
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
    J Med Chem 56:9403-14. 2013
  6. pmc Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem Lett 22:6642-6. 2012
  7. pmc Cyanide toxicity in juvenile pigs and its reversal by a new prodrug, sulfanegen sodium
    Kumar G Belani
    Department of Anesthesiology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Anesth Analg 114:956-61. 2012
  8. pmc Discovery of drugs that possess activity against feline leukemia virus
    Willie M Greggs
    Institute for Molecular Virology, Academic Health Center, University of Minnesota, MN 55455, USA
    J Gen Virol 93:900-5. 2012
  9. pmc Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 6:e15840. 2011
  10. pmc Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA
    Antivir Chem Chemother 23:223-30. 2014

Collaborators

  • Christine L Clouser
  • Herbert T Nagasawa
  • Daune L Crankshaw
  • Andrzej J Bojarski
  • Baek Kim
  • Louis M Mansky
  • Michael J Dapp
  • Krzysztof W Pankiewicz
  • Lauren B Beach
  • Jonathan M Rawson
  • Laurent Bonnac
  • Dominik Rejman
  • Laurent F Bonnac
  • Willie M Greggs
  • Kumar G Belani
  • Ekaterina Paliakov
  • Dae Hwan Suk
  • Liqiang Chen
  • Jeremy L Clark
  • Kyoichi A Watanabe
  • Richard H Heineman
  • Jessica L Martin
  • Erica K Schnettler
  • Harpreet Singh
  • Robert Vince
  • Preeta George
  • David S Beebe
  • Alesia Parker
  • Christine C Dykstra
  • Eric Bennett
  • Francesca Mazzola
  • Martial Say
  • Krzysztof Felczak
  • Guangyao Gao
  • Donald E Macfarlane
  • Lucjan Strekowski
  • Lori Manzel
  • Rashmi Pathak
  • Giulio Magni
  • Maged Henary
  • Qian Ming
  • Martin Kullberg
  • Radek Pohl
  • Lizbeth Hedstrom
  • Hiramagalur N Jayaram
  • Daniel Wilson
  • Magda Olesiak
  • Lieven J Stuyver
  • Phillip A Furman
  • Wojciech J Stec
  • Tamara R McBrayer
  • Laurent Hollecker
  • Michael J Otto
  • Phillip M Tharnish
  • Raymond F Schinazi
  • Stefania Lostia
  • J Christian Mason
  • Hiremagalur N Jayaram
  • Krystyna B Lesiak-Watanabe
  • Gerd Prehna
  • Alokes Majumdar
  • Barry M Goldstein
  • Joel A Yalowitz
  • Michael Seidman
  • Michael D Miller

Detail Information

Publications21

  1. pmc Cyanide antidotes for mass casualties: water-soluble salts of the dithiane (sulfanegen) from 3-mercaptopyruvate for intramuscular administration
    Steven E Patterson
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Med Chem 56:1346-9. 2013
    ..We report the discovery of the highly water-soluble sulfanegen triethanolamine as a promising lead for development as an IM injectable cyanide antidote...
  2. pmc Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA
    Antimicrob Agents Chemother 56:1942-8. 2012
    ..These findings indicate that the combination of decitabine and gemcitabine shows potent antiretroviral activity at nontoxic doses and should be further investigated for clinical relevance...
  3. pmc Novel, orally effective cyanide antidotes
    Herbert T Nagasawa
    Center for Drug Design, University of Minnesota, Minneapolis 55455, USA
    J Med Chem 50:6462-4. 2007
    ..These prodrugs of 3-MP are unique in being not only orally bioavailable, but may be administered up to an hour prior to cyanide as a prophylactic agent and are both rapid- or slow-acting when given parenterally...
  4. pmc 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors
    Jonathan M Rawson
    Institute for Molecular Virology, University of Minnesota, 18 242 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA Molecular and Cellular Developmental Biology and Genetics Graduate Program, Medical School, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem 21:7222-8. 2013
    ..These observations represent the first demonstration of a mild anti-HIV-1 mutagen potentiating the antiretroviral activity of RNRIs and encourage the clinical translation of enhanced viral mutagenesis in treating HIV-1 infection. ..
  5. doi request reprint Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis
    Laurent F Bonnac
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
    J Med Chem 56:9403-14. 2013
    ..This Perspective covers recent advances in the use of promutagenic nucleosides and the Vif-APOBEC interaction as chemotherapeutic strategies for targeting viral mutation rates. ..
  6. pmc Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem Lett 22:6642-6. 2012
    ..These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1...
  7. pmc Cyanide toxicity in juvenile pigs and its reversal by a new prodrug, sulfanegen sodium
    Kumar G Belani
    Department of Anesthesiology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Anesth Analg 114:956-61. 2012
    ..In this study, we induced severe CN toxicity independently with SNP or sodium cyanide (NaCN) in a juvenile pig model to demonstrate reversal of severe CN toxicity with a new antidote, sulfanegen sodium, a prodrug of 3-mercaptopyruvate...
  8. pmc Discovery of drugs that possess activity against feline leukemia virus
    Willie M Greggs
    Institute for Molecular Virology, Academic Health Center, University of Minnesota, MN 55455, USA
    J Gen Virol 93:900-5. 2012
    ..Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use...
  9. pmc Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 6:e15840. 2011
    ..These observations together with a recent ex vivo study with HIV-1, suggest that gemcitabine has broad antiretroviral activity and could be particularly useful in vivo when used in combination drug therapy...
  10. pmc Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs
    Christine L Clouser
    Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA
    Antivir Chem Chemother 23:223-30. 2014
    ..For their current indications, decitabine and gemcitabine are delivered intravenously...
  11. pmc Novel inhibitors of human immunodeficiency virus type 2 infectivity
    Lauren B Beach
    Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA Molecular, Cellular, Developmental Biology and Genetics Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA
    J Gen Virol 95:2778-83. 2014
    ..In addition, the data are consistent with HIV-2 reverse transcriptase being more sensitive than HIV-1 reverse transcriptase to dNTP pool alterations. ..
  12. pmc Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1
    Michael J Dapp
    Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA
    J Virol 88:354-63. 2014
    ....
  13. pmc A novel paradigm for assessing efficacies of potential antidotes against neurotoxins in mice
    Daune L Crankshaw
    Center for Drug Design, Academic Health Center, University of Minnesota, MN, United States
    Toxicol Lett 175:111-7. 2007
    ..This new test paradigm was found to be a powerful tool for assessing the efficacies of some novel antidotes against cyanide and should be equally applicable for evaluating putative antidotes for other neurotoxins...
  14. pmc Exploiting drug repositioning for discovery of a novel HIV combination therapy
    Christine L Clouser
    Institute for Molecular Virology, Medical School, University of Minnesota, 18 242 Moos Tower, 515 Delaware St S E, Minneapolis, MN 55455, USA
    J Virol 84:9301-9. 2010
    ..Such drug combinations are relevant since members of these drug classes are used clinically. Our observations support a model in which increased mutation frequency decreases infectivity through lethal mutagenesis...
  15. pmc Back to the future: revisiting HIV-1 lethal mutagenesis
    Michael J Dapp
    Institute for Molecular Virology, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA
    Trends Microbiol 21:56-62. 2013
    ....
  16. ncbi request reprint Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication
    Jeremy L Clark
    Pharmasset, Inc, 303 A College Road East, Princeton, New Jersey 08540, USA
    J Med Chem 48:5504-8. 2005
    ..Compound 1 shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity...
  17. ncbi request reprint Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase
    Dominik Rejman
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Med Chem 49:5018-22. 2006
    ..Both 8 and 13 (Ki = 20-87 nM) were found to be the most potent cofactor type inhibitors of IMP dehydrogenase...
  18. ncbi request reprint Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides
    Ekaterina Paliakov
    Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
    Bioorg Med Chem 15:324-32. 2007
    ..The CoMFA results derived from several models consistently indicate that electrostatic interactions of the molecules with a biological receptor contribute to biological activities to a greater extent than steric effects...
  19. ncbi request reprint Probing binding requirements of NAD kinase with modified substrate (NAD) analogues
    Laurent Bonnac
    Center for Drug Design, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem Lett 17:1512-5. 2007
    ..An uncharged benzamide adenine dinucleotide (BAD) was found to be the most potent competitive inhibitor (K(i)=90 microM) of the human enzyme reported so far...
  20. ncbi request reprint Phosphonoxins: rational design and discovery of a potent nucleotide anti-Giardia agent
    Dae Hwan Suk
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA
    Bioorg Med Chem Lett 17:2811-6. 2007
    ..Phosphonoxins, a new class of synthetic, rationally designed anti-microbial agents, are described. From this class a sub-micromolar inhibitor of Giardia trophozoite growth has been identified...
  21. ncbi request reprint Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia
    Krzysztof W Pankiewicz
    Pharmasset Inc, 1860 Montreal Road, Tucker, Georgia 30084, USA
    J Med Chem 45:703-12. 2002
    ..These results show that C2-MAD and C4-MAD may be of therapeutic interest in the treatment of human leukemias...